|
IMPACTT Newsletter | August 2022
|
|
|
|
|
Welcome to our August 2022 IMPACTT newsletter! Keep reading for news, events, and publications in the microbiome world.
|
|
|
|
|
|
Free Resource:
IMPACTT Microbiome Standards
Introducing: The IMPACTT Microbiome Standards! We have 4 standards available with the same bacterial community spike-in: 3 are encased in human fecal matrix from different donors, and 1 is in PBS. Our community spike-in is made up of 45 bacterial species that are phylogenetically diverse and evenly distributed.
|
The best part? They're free for Canadian labs! Not in Canada? Just pay shipping. All we ask in return is that you participate in our benchmarking exercise to improve the field of microbiome research.
|
|
|
|
|
IMPACTT TEAM & NETWORK NEWS
|
|
|
Erasmus Summer Programme Talk given by Dr. Anita Kozyrskyj
Dr. Anita Kozyrskyj (Platform 2 Lead) gave a talk on 26 Aug 2022 called The Rise to Power of the Microbiome: Sample Size Calculations at the Erasmus Summer Programme 2022. The Erasmus Medical Centre is home to the Erasmus University Faculty of Medicine, and each summer hosts a three-week program with courses and talks for MSc, PhD, and medical students/professionals on state-of-the-art biomedical topics such as clinical medicine, general practice, public health, epidemiology, genetics, and biostatistics.
|
Human Research Ethics Interview with Dr. Diego Silva
|
Dr. Diego Silva (Ethics Lead) was interviewed for an article in The Sydney Morning Herald about ethics considerations when conducting studies with human subjects. This is in relation to a controversial study being conducted in hospitals across Victoria, Australia to determine the optimum level of oxygen support to use for premature infants that is not seeking consent from parents. Read the article here.
|
|
|
|
|
|
New IMPACTT Publication
|
Bishop et al. (including Platform 2 Lead Dr. Anita Kozyrskyj and Platform 4 Co-Lead Dr. Ian Lewis as senior authors). Mucosal Immunology. 15 Aug 2022.
|
|
Highlights: This IMPACTT review examines the experimental and computational tools that can provide insights into the molecular mechanisms at work in host-microbiome interactions and to highlight the undeveloped frontiers that are currently holding back microbiome research from fully leveraging the benefits of modern metabolomics.
|
|
|
|
New Publications in the Microbiome World
|
Federici et al. Cell. 04 Aug 2022.
|
Highlights: In this study, researchers identified a clade of Klebsiella pneumoniae strains with unique antibiotic resistance that were strongly associated with disease exacerbation and severity in patients with inflammatory bowel disease (IBD). This was confirmed in gnotobiotic colitis mouse models. The researchers then showed that a K. pneumoniae five-phage combination was able to suppress K. pneumoniae strains in these mouse models, leading to reduced intestinal inflammation. They also conducted a proof-of-concept assessment of these phages in an artificial human gut and in healthy volunteers, demonstrating the feasibility of this orally administered combination phage therapy.
|
|
Podlesny et al. (including IMPACTT Co-Applicant Dr. Jens Walter). Cell Reports Medicine. 04 Aug 2022.
|
Highlights: In this study, researchers performed a comprehensive fecal metagenome analysis of 14 fecal microbiota transplantation (FMT) trials for a variety of medical conditions, with a combined total of 254 recipients and 222 stool donors. They used metagenomics shotgun sequence data to determine the origins of bacterial strains in patients after FMT and found that donor strain engraftment was strongly positively correlated with microbiota dysbiosis in recipients pre-FMT. Along these lines, donor strain engraftment was more successful when FMT was preceded by antibiotic treatment and bowel lavage. Based on these results, the researchers developed generalizable models to predict and control FMT outcomes and determine the relationship between post-FMT microbiota assembly and clinical response.
|
|
Guitor et al. Microbiome. 26 Aug 2022.
|
|
Highlights: In this study, researchers used a targeted capture approach to compare the gut resistome (the collection of antibiotic resistance genes) of preterm infants to determine if probiotic use in preterm infants has beneficial effects on the resistome. They collected stool samples for two groups of infants – those that routinely received a multi-strain probiotic during hospitalization and those that did not – as well as samples from full-term infants, and found over 80 antibiotic resistance genes in the preterm infants that did not receive probiotics that were not found in either the full-term or probiotic-supplemented preterm infants. This pilot survey showed that probiotics administered after preterm birth during hospitalization reduced the diversity and prevented persistence of antibiotic resistance genes in the gut microbiome.
|
|
New Publications from our IMPACTT Team and Network
|
Dr. Anita Kozyrskyj (Platform 2 Lead) and Dr. Stuart Turvey, Dr. Padmaja Subbarao, & Dr. Meghan Azad (CMI2 Team Grant Leads)
|
Obiakor et al. Antibiotics. 21 Jul 2022.
|
|
Dr. Michael Surette, Dr. Tony Lam, Dr. André Marette, & Dr. Jonathan Schertzer (CMI2 Team Grant Leads)
|
Anhê et al. Gut. 25 Aug 2022.
|
|
Dr. Kathy McCoy (IMPACTT Director & Platform 1 Lead)
|
Sinnberg et al. American Journal of Respiratory and Critical Care Medicine. 04 Aug 2022.
|
|
Dr. Paul Kubes (Platform 1 Co-Lead)
|
Kratofil et al. Nature. 10 Aug 2022.
|
|
Dr. Celia Greenwood (Platform 5 Lead)
|
Lebeau et al. Nucleic Acids Research. 26 Aug 2022.
|
Lu et al. Biological Psychiatry. 22 Aug 2022.
|
|
Dr. Braedon McDonald (Education Co-Lead)
|
Evans et al. PLOS One. 25 Aug 2022.
|
|
Dr. John Conly (IMPACTT Co-Applicant)
|
Muram et al. Journal of Neurosurgery. 02 Aug 2022.
|
Leal et al. Antimicrobial Resistance & Infection Control. 11 Aug 2022.
|
|
Dr. Irina Dinu (IMPACTT Co-Applicant)
|
Khaira et al. Cardiology in the Young. 24 Aug 2022.
|
|
Dr. Janet Hill (IMPACTT Co-Applicant)
|
Singh et al. Theriogenology. 20 Aug 2022.
|
|
Dr. Jens Walter (IMPACTT Co-Applicant)
|
FitzGerald et al. Gut Microbes. 02 Aug 2022.
|
|
Lifestyles in transition: evolution and natural history of the genus Lactobacillus
|
Duar et al. FEMS Microbiology Reviews.
|
|
Dr. Meghan Azad (CMI2 Team Grant Lead)
|
Kumbhare et al. Cell Reports Medicine. 26 Aug 2022.
|
|
Dr. Zulfiqar Bhutta (CMI2 Team Grant Lead)
|
Arvay et al. The Lancet Global Health. 09 Aug 2022.
|
CBD 2019 LRI Collaborators. The Lancet Infectious Diseases. 11 Aug 2022.
|
Samad et al. Global Heart. 18 Aug 2022.
|
Lelijveld et al. The Lancet Child & Adolescent Health. 24 Aug 2022.
|
Villar et al. The Lancet Diabetes & Endocrinology. 26 Aug 2022.
|
|
Dr. Adam Burgener (CMI2 Team Grant Lead)
|
Bunjun et al. Clinical Infectious Diseases. 09 Aug 2022.
|
|
Dr. Jeremy Hirota (CMI2 Team Grant Lead)
|
Jozani et al. The Canadian Journal of Chemical Engineering. 31 Jul 2022.
|
|
Dr. David Mack (CMI2 Team Grant Lead)
|
De Nanassy et al. Journal of Surgical Case Reports. 05 Aug 2022.
|
|
Dr. André Marette (CMI2 Team Grant Lead)
|
George et al. Antibiotics. 19 Jul 2022.
|
Song et al. Basic & Clinical Pharmacology & Toxicology. 16 Aug 2022.
|
Fleury et al. Physiological Reports. 01 Aug 2022.
|
|
Dr. Aleixo Muise (CMI2 Team Grant Lead)
|
Dirvanskyte. Journal of Crohn’s and Colitis. 30 Jul 2022.
|
|
Dr. Roger Paredes (CMI2 Team Grant Lead)
|
Tarín-Vicente et al. The Lancet. 26 Aug 2022.
|
Santoro et al. Journal of Global Antimicrobial Resistance. 07 Aug 2022.
|
Xie et al. JAMA Internal Medicine. 18 Aug 2022.
|
|
Dr. Jonathan Schertzer (CMI2 Team Grant Lead)
|
Duggan et al. Physiological Reports. 22 Aug 2022.
|
|
Dr. Stuart Turvey (CMI2 Team Grant Lead)
|
Gazzaz et al. American Journal of Medical Genetics. 10 Aug 2022.
|
|
Bell et al. Computational and Structural Biotechnology Journal. 19 Aug 2022.
|
|
|
|
|
UPCOMING EVENTS AND REMINDERS
|
|
|
|
|
Click here to see curated lists of upcoming events in the microbiome world
|
|
|
|
|
|
CALL FOR PAPERS
|
|
|
|
|
|
Be a contributor to our microbiome community!
|
|
|
|
|
|
|
|
|
|
|
|
|
|
